Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
Search results
511 results
-
-
Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]
In development [GID-TA10119] Expected publication date: TBC
-
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
In development [GID-TA10780] Expected publication date: TBC
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]
In development [GID-TA10314] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma ID3856
In development [GID-TA10836] Expected publication date: TBC
-
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535
In development [GID-TA10412] Expected publication date: TBC
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
In development [GID-TA10768] Expected publication date: TBC
-
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]
In development [GID-TA10442] Expected publication date: TBC
-
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404
In development [GID-TA10327] Expected publication date: TBC